BIOA 8-K
BioAge Labs, Inc. (BIOA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2025, BioAge Labs, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
|
|
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
|
99.1 |
|
Press release issued by BioAge Labs, Inc. dated August 6, 2025. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
BIOAGE LABS, INC. |
|
|
|
|
Date: |
August 6, 2025 |
By: |
/s/ Dov Goldstein |
|
|
|
Dov Goldstein, M.D. |
Exhibit 99.1
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business
Updates
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end
Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules
Strengthened discovery platform through molecular profiling of 17,000+ samples from leading European HUNT Biobank
EMERYVILLE, Calif.--BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business updates and reported its second quarter 2025 financial results.
“In Q2 2025, BioAge achieved key milestones across our clinical pipeline and discovery platform,” said Kristen Fortney, CEO and co-founder of BioAge. “We completed IND-enabling studies for our potential best-in-class oral NLRP3 inhibitor, BGE-102, positioning us to initiate Phase 1 trials later this year, with initial SAD data expected by year-end. We strengthened our apelin pipeline by securing a partnership for potent APJ agonist antibodies and filing patent applications for novel oral small molecules. We also launched a collaboration with the HUNT Biobank to generate millions of new data points, fueling our analysis of human longevity. I’m proud of our progress as we advance our mission to develop transformative therapies for metabolic diseases.”
Second Quarter 2025 Business Highlights
NLRP3 inhibitor program development
APJ agonist pipeline expansion
Discovery platform expansion
Strategic partnerships
Second Quarter 2025 Financial Results
Research and development expenses were $19.8 million for the quarter ended June 30, 2025, compared to $10.5 million for the same period in 2024. The $9.3 million increase in research and development expenses was primarily attributable to a $8.0 million increase in direct costs related to licensing, discovery, and development activities related to our novel apelin receptor APJ agonist programs. Additionally contributing to the increase in research and development expenses was a $3.0 million increase in direct costs related to our BGE-102 program associated with IND-enabling activities and drug-product manufacturing. These higher costs were partially offset by a $1.7 million reduction in azelaprag direct costs as development was terminated in January 2025.
General and administrative expenses were $7.3 million for the quarter ended June 30, 2025, compared to $4.8 million for the same period in 2024. The $2.5 million increase was primarily
attributable to a $1.5 million increase in personnel-related expenses, which was largely attributable to increased stock-based compensation expense associated with option grants issued to employees, executives, board members and advisors. Additionally, contributing to the increase was a $0.9 million increase in legal fees.
Net loss was $21.6 million for the quarter ended June 30, 2025, or $0.60 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $13.6 million, or $7.94 per weighted-average common share outstanding, basic and diluted, for the same period in 2024.
As of June 30, 2025, BioAge had approximately $313.4 million in cash, cash equivalents, and marketable securities. Based on our current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. Initiation of a Phase 1 SAD/MAD trial is planned for the second half of 2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, the sufficiency of our cash and cash equivalents, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the
timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading “Risk Factors” included in BioAge’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on August 6, 2025, and BioAge’s other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts
PR: Chris Patil, [email protected]
IR: Dov Goldstein, [email protected]
Partnering: [email protected]
Web: https://bioagelabs.com
BIOAGE LABS, INC.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share information)
|
|
Three Months Ended |
|
|||||
|
|
June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Collaboration revenue |
|
$ |
2,412 |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
$ |
19,844 |
|
|
$ |
10,471 |
|
General and administrative |
|
|
7,339 |
|
|
|
4,798 |
|
Total operating expenses |
|
|
27,183 |
|
|
|
15,269 |
|
Loss from operations |
|
|
(24,771 |
) |
|
|
(15,269 |
) |
Other income (expense) |
|
|
|
|
|
|
||
Interest expense |
|
|
(201 |
) |
|
|
(443 |
) |
Interest and other income (expense), net |
|
|
3,420 |
|
|
|
2,201 |
|
Gain (loss) from changes in fair value of warrants |
|
|
(11 |
) |
|
|
(70 |
) |
Total other income (expense), net |
|
|
3,208 |
|
|
|
1,688 |
|
Net loss |
|
$ |
(21,563 |
) |
|
$ |
(13,581 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.60 |
) |
|
$ |
(7.94 |
) |
Weighted-average common shares outstanding, basic and dilutive |
|
|
35,850,037 |
|
|
|
1,711,005 |
|
Comprehensive loss: |
|
|
|
|
|
|
||
Net loss |
|
|
(21,563 |
) |
|
|
(13,581 |
) |
Other comprehensive income (loss): |
|
|
|
|
|
|
||
Foreign currency translation adjustment |
|
|
(52 |
) |
|
|
(18 |
) |
Total other comprehensive income (loss): |
|
|
(52 |
) |
|
|
(18 |
) |
Total comprehensive loss |
|
$ |
(21,615 |
) |
|
$ |
(13,599 |
) |
BIOAGE LABS, INC.
Unaudited Condensed Consolidated Balance Sheets
(in thousands, except share and per share information)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2025 |
|
|
2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current Assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
220,330 |
|
|
$ |
354,349 |
|
Marketable securities, current |
|
|
76,965 |
|
|
|
— |
|
Accounts receivable |
|
|
603 |
|
|
|
— |
|
Prepaid expenses and other current assets |
|
|
3,799 |
|
|
|
2,754 |
|
Total current assets |
|
|
301,697 |
|
|
|
357,103 |
|
Investments |
|
|
100 |
|
|
|
100 |
|
Marketable securities |
|
|
16,108 |
|
|
|
— |
|
Property and equipment, net |
|
|
974 |
|
|
|
591 |
|
Operating lease right-of-use assets, net |
|
|
3,032 |
|
|
|
200 |
|
Other assets |
|
|
237 |
|
|
|
240 |
|
Total assets |
|
$ |
322,148 |
|
|
$ |
358,234 |
|
Liabilities |
|
|
|
|
|
|
||
Current Liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,329 |
|
|
$ |
1,996 |
|
Accrued expenses and other current liabilities |
|
|
7,584 |
|
|
|
11,751 |
|
Term loan, current |
|
|
5,596 |
|
|
|
6,000 |
|
Operating lease liabilities, current |
|
|
630 |
|
|
|
202 |
|
Deferred revenue, current |
|
|
7,698 |
|
|
|
7,826 |
|
Total current liabilities |
|
|
22,837 |
|
|
|
27,775 |
|
Deferred revenue |
|
|
1,902 |
|
|
|
4,674 |
|
Term loan |
|
— |
|
|
|
2,502 |
|
|
Warrant liability |
|
|
108 |
|
|
|
156 |
|
Operating lease liabilities |
|
|
2,520 |
|
|
|
— |
|
Total liabilities |
|
|
27,367 |
|
|
|
35,107 |
|
Stockholders’ Equity |
|
|
|
|
|
|
||
Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of |
|
|
— |
|
|
|
— |
|
Common stock, $0.00001 par value; 500,000,000 shares authorized as of |
|
|
— |
|
|
|
— |
|
Additional paid-in-capital |
|
|
581,871 |
|
|
|
575,693 |
|
Accumulated other comprehensive income |
|
|
212 |
|
|
|
245 |
|
Accumulated deficit |
|
|
(287,302 |
) |
|
|
(252,811 |
) |
Total stockholders’ equity |
|
|
294,781 |
|
|
|
323,127 |
|
Total liabilities and stockholders’ equity |
|
$ |
322,148 |
|
|
$ |
358,234 |
|